Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Gilead’s new drug Vemlidy (Tenofovir Alafenamide Fumarate, 25 mg, once a day) was approved by the US FDA for chronic hepatitis B virus infection in compensated liver disease. Vemlidy is an innovative targeted tenofovir prodrug. Compared with the previous product Viread (tenofovir disoproxil fumarate, tenofovirdisoproxilfumarate) 300mg, it only needs less than one-tenth of the dose. Obtain similar antiviral effects.
Product Categories : API Intermediates > Tenofovir Alafenamide Fumarate Intermediate
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.